Innate Pharma Files 6-K, Appoints New CEO
Ticker: IPHYF · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, leadership-change, sec-filing
TL;DR
Innate Pharma 6-K: New CEO Johnathan Dickinson appointed, Irina Staatz-Granzer quoted.
AI Summary
Innate Pharma S.A. filed a Form 6-K on October 14, 2024, reporting information as of October 14, 2024. The filing includes details about the company's principal executive office in Marseille, France, and confirms that the registrant files annual reports under Form 20-F. The document also references exhibit 99.1, which contains quotes from Irina Staatz-Granzer, Chairwoman of the Supervisory Board, and Johnathan Dickinson, appointed Chief Executive Officer and Chairman of the Executive Board.
Why It Matters
This filing provides an update on Innate Pharma's corporate governance and leadership, potentially signaling strategic shifts under new executive appointments.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate information and leadership updates, with no immediate financial or operational risks indicated.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- Johnathan Dickinson (person) — Appointed Chief Executive Officer and Chairman of the Executive Board
- Irina Staatz-Granzer (person) — Chairwoman of the Supervisory Board
- October 14, 2024 (date) — Report Date
- Marseille, France (location) — Principal executive office
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as of October 14, 2024, including details about the company's principal executive office and confirmation of filing annual reports under Form 20-F.
Who has been appointed as the new Chief Executive Officer and Chairman of the Executive Board of Innate Pharma?
Johnathan Dickinson has been appointed as the new Chief Executive Officer and Chairman of the Executive Board of Innate Pharma.
Who is Irina Staatz-Granzer in relation to Innate Pharma?
Irina Staatz-Granzer is the Chairwoman of the Supervisory Board of Innate Pharma S.A.
Where is Innate Pharma S.A.'s principal executive office located?
Innate Pharma S.A.'s principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma file annual reports under Form 20-F or Form 40-F?
Innate Pharma files annual reports under cover of Form 20-F.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-10-15 06:11:47
Filing Documents
- a6k-iphx241014.htm (6-K) — 11KB
- exhibit991-241014.htm (EX-99.1) — 18KB
- 0001598599-24-000077.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date October 14, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer